Cipla Results

Cipla Q4 profit plunges 55% to ₹554.6 cr amid US drag, higher R&D spend

Drugmaker cites lower contribution from key US products, higher R&D investments and rising operating costs as Q4 FY26 profit declines sharply

Cipla Q4 results: Net profit falls 54.6% to ₹555 crore, revenue drops 2.8%

Total revenue from operations fell 2.8 per cent to ₹6,541 crore, below the average expectations of ₹6,749 crore, hurt by a sales decline in its key North America market

Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

Q4 results today: Airtel, Oil India, TVS Motors, Cipla, 94 others on May 13

Q4FY26 company results: Firms including ata Motors Commercial Vehicles, Hindustan Petroleum, DLF, and TVS Holdings are also to release their January-March earnings today

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

Cipla Q3 results: Net profit slumps 57% to ₹675 crore on US supply issues

Bets on respiratory product launches and peptides for growth

Cipla Q3FY26 results: Profit falls 57% to ₹676 crore, revenue flat

Cipla Q3 Results: The decline in Cipla's profit was primarily due to a production halt at the exclusive manufacturer of Lanreotide, the company's second-largest revenue-contributing tumour drug

Cipla Q2 results: Profit rises 4%, revenue hits record ₹7,589 crore

The company bets on Eli Lilly tie-up for GLP-1 drug, biosimilars expansion; reaffirms $1 billion US revenue goal

Cipla's global CEO Umang Vohra to step down, COO Achin Gupta to take over

Umang Vohra was responsible for leading Cipla through a phase of strategic transformation, strengthening its global leadership in respiratory therapies, and digital and manufacturing capabilities

Cipla Q2FY26 results: Net profit rises 3.7% to ₹1,353 cr on higher revenue

Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, Cipla Ltd said in a regulatory filing. Consolidated total revenue from operations in the second quarter stood at Rs 7,589.44 crore, as against Rs 7,051.02 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 6,004.86 crore, as compared to Rs 5,452.57 crore in the corresponding period last fiscal, the company said. In the second quarter, the pharmaceuticals segment clocked revenue of Rs 7,291.43 crore, as against Rs 6,775.56 crore in the same period a year ago. New ventures registered revenue of Rs 350.68 crore, as against Rs 319.6 crore, the filing said.

Cipla Q2 preview: Pharma major may see stable qtr; check key estimates here

Cipla is expected to report a profit after tax (PAT) of ₹1,361.6 crore for the September 2025 quarter, against ₹1,302.5 crore in Q2FY25

Stock market close highlights: Sensex drops 721 pts, Nifty at 24,837; Bajaj twins fall up to 5%

Sensex Today | Stock market close highlights on Friday, July 25, 2025: In the broader markets, the Nifty MidCap index fell 1.61 per cent, and the Nifty SmallCap index edged 2.1 per cent lower

Cipla Q1 FY26 result: Net profit jumps 10% at ₹1,298 cr, income rises 4%

The company said that its revenue fro the One-India business (operations within India) grew 6 per cent year-on-year, crossing ₹3,000 crore for the first time in any opening quarter of a financial year

Q1 results today: Cipla, SAIL, Bank of Baroda among 85 firms on July 25

Q1 FY26 company results, July 25: Bajaj Finserv, Shriram Finance, Reliance Infrastructure, Orient Cement, and ACME Solar will also release their April-June quarter earnings reports today

Cipla shares at ₹1,800 or ₹1,465? Analysts divided on pharma stock post Q4

Cipla share price today: Cipla shares today declined 2.9 per cent intraday to hit a low of ₹1,474.1 per share

Cipla Q4FY25 results: Net profit zooms 30% to ₹1,221 cr, revenue up 9%

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent

Cipla Q4 result: Profit rises 30% to ₹1,222 cr; special dividend declared

Cipla Q4 FY25 result: Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share

Q4 results today: Cipla, Hero Moto, Airtel, Siemens, Tata Motors on May 13

Q4 FY25 company results: GAIL (India), Aditya Birla Capital, and GlaxoSmithKline Pharmaceuticals will also be releasing their Jan-March quarter results on May 13

Stocks to watch today, May 13: Tata Motors, Airtel, GAIL, Cipla, Tata Steel

In the previous trading session, Sensex jumped 2,975.43 points, or 3.7 per cent, to close at 82,429.90 levels. The Nifty50 closed at 24,924.7, up by 916.7 points, or 3.8 per cent.

Cipla share price jumps 5% as USFDA okays cancer drug Paclitaxel

Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10